Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. DBD
DBD logo

DBD Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Diebold Nixdorf Inc (DBD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
85.640
1 Day change
1.35%
52 Week Range
89.050
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Diebold Nixdorf Inc (DBD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong financial performance, positive analyst sentiment, and hedge fund buying activity, which align with a long-term growth outlook. Despite no immediate trading signals or recent congress trading data, the overall fundamentals and catalysts make it a favorable investment.

Technical Analysis

The technical indicators suggest a neutral to slightly bullish trend. The MACD is positive and contracting, RSI is neutral at 51.374, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 83.597, and resistance is at 88.204, with the stock trading near its pivot point of 85.9.

Options Data

Neutral
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
2
Buy
9

Positive Catalysts

  • Analysts have raised price targets to $100 and maintain Buy/Outperform ratings, citing strong Q4 results and positive 2026 guidance.

  • Hedge funds are significantly increasing their positions, with a 200.38% increase in buying activity.

  • The company reported strong financial growth, including an 813.33% YoY EPS increase and a 785.71% YoY net income increase.

Neutral/Negative Catalysts

  • Millstreet Capital Management sold a portion of its shares, which could signal reduced confidence from one institutional investor.

  • The stock has a mixed short-term trend outlook, with a 50% chance of slight declines in the next day and month.

Financial Performance

Diebold Nixdorf reported strong financial results for 2025/Q4, with revenue increasing by 11.66% YoY to $1.1042 billion, net income surging by 785.71% YoY to $49.6 million, and EPS growing by 813.33% YoY to 1.37. The gross margin also improved by 13.51% YoY to 27.14%. The company expects continued growth in 2026, with revenue projected at $3.94 billion and adjusted EBITDA at $484.8 million.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are bullish on Diebold Nixdorf, with Wedbush and DA Davidson raising price targets from $80 to $100 and maintaining Outperform/Buy ratings. They highlight strong order entry, backlog growth, and positive momentum expected to continue into 2026.

Wall Street analysts forecast DBD stock price to fall
2 Analyst Rating
Wall Street analysts forecast DBD stock price to fall
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 84.500
sliders
Low
80
Averages
80
High
80
Current: 84.500
sliders
Low
80
Averages
80
High
80
Wedbush
Outperform
maintain
$80 -> $100
AI Analysis
2026-02-13
Reason
Wedbush
Price Target
$80 -> $100
AI Analysis
2026-02-13
maintain
Outperform
Reason
Wedbush raised the firm's price target on Diebold to $100 from $80 and keeps an Outperform rating on the shares. While broader markets were under pressure, Diebold reported strong Q4 results and 2026 guidance, with full year EPS of $5.50 exceeding consensus estimate of $4.87, the firm notes. Wedbush come out of earnings incrementally more positive, and expects the momentum the company enjoyed in 2025 will carry through 2026 with this year in many ways mirroring last.
DA Davidson
Matt Summerville
Buy
maintain
$80 -> $100
2026-02-13
Reason
DA Davidson
Matt Summerville
Price Target
$80 -> $100
2026-02-13
maintain
Buy
Reason
DA Davidson analyst Matt Summerville raised the firm's price target on Diebold to $100 from $80 and keeps a Buy rating on the shares. The company continues to experience healthy order entry and backlog, inclusive of 9 logos added within its growing North America Retail platform, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for DBD
Unlock Now

People Also Watch